InRange publication
InRange diabetes type 1
CGM-based Time-in-Range Using Insuln Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Type 1 Diabetes: The Head-to-Head Randomized Controlled in Range Trial
Tadej Battelino MD, PhD,Thomas Danne MD,Steve V Edelman MD,Pratik Choudhary MD,Eric Renard MD,Jukka Westerbacka MD, PhD,Bhaswati Mukherjee MD,Valerie Pilorget MD,Mathieu Coudert MSc,Richard M Bergenstal MD
Diabetes Obes Metab. 2022; 1- 11. doi:10.1111/dom.14898
See the result of the InRange study here
Learn more about TiR, the study
design and result of InRange
Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!
Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4
Autoimmune Type 1 Diabetes
The Type 1 Diabetes (T1D) field is evolving.
Recognition of the presymptomatic stages in T1D is growing.1-4
The clinical benefits of early detection of T1D are being highlighted.3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.1,2
